Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$255.98 CAD
Change Today +1.76 / 0.69%
Volume 340.8K
VRX On Other Exchanges
Symbol
Exchange
Toronto
New York
Frankfurt
As of 4:00 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

J. Michael Pearson

Chairman and Chief Executive Officer, Valeant Pharmaceuticals International, Inc.
AgeTotal Calculated CompensationThis person is connected to 30 board members in 7 different organizations across 7 different industries.

See Board Relationships
55$10,275,928
As of Fiscal Year 2014

Background*

Mr. J. Michael Pearson, also known as Mike, has been the Chief Executive Officer and President at Solta Medical, Inc. since January 2014. Mr. Pearson has been the Chief Executive Officer and President of Obagi Medical Products, Inc. since April 25, 2013. He joined Valeant in February 2008 as Chairman and Chief Executive Officer. He has been Chairman and Chief Executive Officer at Valeant Pharmaceuticals International since February 2008. Prior to joining Valeant, he ...

Read Full Background

Corporate Headquarters*

2150 St. Elzéar boulevard West
Laval, Quebec H7L 4A8

Canada

Phone: 514-744-6792
Fax: 514-744-6272

Board Members Memberships*

Director and Head of Global Pharmaceutical Practice and Head of Mid-Atlantic Region
2008-N/A
Former Chairman and Chief Executive Officer
2010-Present
Chairman and Chief Executive Officer
2013-Present
Chief Executive Officer, President and Director
2014-Present
Chief Executive Officer, President and Director
2015-Present
Director

Education*

BS
Duke University
BSE
Duke University
MBA
University of Virginia

Other Affiliations*

Annual Compensation*

Salary$1,907,693
Total Annual Compensation$1,907,693

Stock Options*

All Other Compensation$368,235
Exercisable Options4,444,659
Exercisable Options Value$588,993,770
Unexercisable Options488,469
Unexercisable Options Value$58,381,953
Total Value of Options$647,375,722
Total Number of Options4,933,128

Total Compensation*

Total Annual Cash Compensation$10,275,928
Total Short Term Compensation$1,907,693
Other Long Term Compensation$368,235
Total Calculated Compensation$10,275,928
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRX:CN C$255.98 CAD +1.76

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Dilip Shantilal Shanghvi Managing Director, Executive Director and Member of Shareholders/Investors Grievance Committee
Sun Pharmaceutical Industries Limited
23.1M
Heather Bresch Chief Executive Officer, Executive Director and Member of Science & Technology Committee
Mylan N.V.
$1.1M
Joseph C. Papa Chairman, Chief Executive Officer and President
Perrigo Company Public Limited Company
$1.1M
Haruo Naito Chief Executive Officer, Representative Corporate Officer and Director
Eisai Co., Ltd.
¥115.0M
Yoshihiko Hatanaka Chief Executive Officer, President and Representative Director
Astellas Pharma, Inc.
¥170.0M
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VALEANT PHARMACEUTICALS INTE, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.